Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)
Inhibikase Therapeutics (IKT) has disclosed Debt Ratio for 6 consecutive years, with 0.0 as the latest value for Q2 2025.
- On a quarterly basis, Debt Ratio fell 97.52% to 0.0 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.0, a 97.52% decrease, with the full-year FY2024 number at 0.0, down 89.17% from a year prior.
- Debt Ratio was 0.0 for Q2 2025 at Inhibikase Therapeutics, down from 0.0 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.03 in Q3 2024 to a low of 0.0 in Q2 2025.
- A 5-year average of 0.01 and a median of 0.01 in 2022 define the central range for Debt Ratio.
- Peak YoY movement for Debt Ratio: soared 298.06% in 2024, then crashed 97.52% in 2025.
- Inhibikase Therapeutics' Debt Ratio stood at 0.01 in 2021, then rose by 15.64% to 0.01 in 2022, then skyrocketed by 76.92% to 0.01 in 2023, then plummeted by 89.17% to 0.0 in 2024, then crashed by 61.9% to 0.0 in 2025.
- Per Business Quant, the three most recent readings for IKT's Debt Ratio are 0.0 (Q2 2025), 0.0 (Q1 2025), and 0.0 (Q4 2024).